文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

微轴流泵或标准治疗用于梗死相关心源性休克

Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.
PubMed 文献 · N Engl J Med · 2024-04-07
一句话结论STEMI合并心源性休克患者常规使用微轴流泵(Impella CP)加标准治疗较单用标准治疗降低180天全因死亡风险,但复合不良事件发生率更高。

这项国际多中心随机试验纳入360例STEMI合并心源性休克患者,随机分配至微轴流泵(Impella CP)加标准治疗组或单用标准治疗组,最终分析355例(微轴流泵组179例、标准治疗组176例)。180天全因死亡在微轴流泵组为45.8%(82/179),标准治疗组为58.5%(103/176),风险比0.74(95%CI 0.55~0.99,P=0.04)。复合安全终点事件在微轴流泵组为24.0%(43例),标准治疗组为6.2%(11例),相对风险4.74(95%CI 2.36~9.55);肾脏替代治疗在微轴流泵组为41.9%(75例),标准治疗组为26.7%(47例),相对风险1.98(95%CI 1.27~3.09)。作者结论认为,STEMI相关心源性休克患者常规使用微轴流泵加标准治疗较单用标准治疗降低180天全因死亡风险,但复合不良事件发生率更高。

要点

  • STEMI合并心源性休克患者,微轴流泵(Impella CP)加标准治疗组180天全因死亡45.8%(82/179),标准治疗组58.5%(103/176),HR 0.74(95%CI 0.55~0.99,P=0.04)。
  • 微轴流泵组复合安全终点事件(严重出血、肢体缺血、溶血、装置故障或主动脉瓣反流加重)24.0%(43例),标准治疗组6.2%(11例),RR 4.74(95%CI 2.36~9.55)。
  • 微轴流泵组接受肾脏替代治疗41.9%(75例),标准治疗组26.7%(47例),RR 1.98(95%CI 1.27~3.09)。
  • 最终分析355例(微轴流泵组179例、标准治疗组176例),中位年龄67岁,男性79.2%。
  • 作者结论:常规使用微轴流泵加标准治疗较单用标准治疗降低180天全因死亡风险,但复合不良事件发生率更高。

适用人群与场景

  • STEMI合并心源性休克的患者,国际多中心随机试验纳入360例,最终分析355例(微轴流泵组179例、标准治疗组176例)。

处置流程与药物剂量

  • 微轴流泵组:使用微轴流泵(Impella CP)加标准治疗;标准治疗组:单用标准治疗。

研究设计与关键结果

  • 研究类型:国际多中心随机试验;样本量:随机360例,最终分析355例(微轴流泵组179例、标准治疗组176例);人群:STEMI合并心源性休克患者;干预与对照:微轴流泵(Impella CP)加标准治疗 vs 单用标准治疗。
  • 主要终点:180天全因死亡在微轴流泵组45.8%(82/179),标准治疗组58.5%(103/176),HR 0.74(95%CI 0.55~0.99,P=0.04)。
  • 复合安全终点(严重出血、肢体缺血、溶血、装置故障或主动脉瓣反流加重):微轴流泵组24.0%(43例),标准治疗组6.2%(11例),RR 4.74(95%CI 2.36~9.55)。
  • 肾脏替代治疗:微轴流泵组41.9%(75例),标准治疗组26.7%(47例),RR 1.98(95%CI 1.27~3.09)。
  • 患者中位年龄67岁,男性79.2%。

证据类型、等级与局限

  • 证据类型:国际多中心随机试验;资助:丹麦心脏基金会(Danish Heart Foundation)和Abiomed;注册号:ClinicalTrials.gov NCT01633502。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于STEMI合并心源性休克患者,作者结论认为常规使用微轴流泵(Impella CP)加标准治疗较单用标准治疗降低180天全因死亡风险,但复合不良事件发生率更高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The effects of temporary mechanical circulatory support with a microaxial flow pump on mortality among patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock remains unclear.

METHODS: In an international, multicenter, randomized trial, we assigned patients with STEMI and cardiogenic shock to receive a microaxial flow pump (Impella CP) plus standard care or standard care alone. The primary end point was death from any cause at 180 days. A composite safety end point was severe bleeding, limb ischemia, hemolysis, device failure, or worsening aortic regurgitation.

RESULTS: A total of 360 patients underwent randomization, of whom 355 were included in the final analysis (179 in the microaxial-flow-pump group and 176 in the standard-care group). The median age of the patients was 67 years, and 79.2% were men. Death from any cause occurred in 82 of 179 patients (45.8%) in the microaxial-flow-pump group and in 103 of 176 patients (58.5%) in the standard-care group (hazard ratio, 0.74; 95% confidence interval [CI], 0.55 to 0.99; P = 0.04). A composite safety end-point event occurred in 43 patients (24.0%) in the microaxial-flow-pump group and in 11 (6.2%) in the standard-care group (relative risk, 4.74; 95% CI, 2.36 to 9.55). Renal-replacement therapy was administered to 75 patients (41.9%) in the microaxial-flow-pump group and to 47 patients (26.7%) in the standard-care group (relative risk, 1.98; 95% CI, 1.27 to 3.09).

CONCLUSIONS: The routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. The incidence of a composite of adverse events was higher with the use of the microaxial flow pump. (Funded by the Danish Heart Foundation and Abiomed; DanGer Shock ClinicalTrials.gov number, NCT01633502.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Møller JE, Engstrøm T, Jensen LO, et al. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med. 2024. PMID: 38587239. doi:10.1056/NEJMoa2312572

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。